Article Details
Retrieved on: 2025-04-07 18:55:33
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the decision by the Centers for Medicare & Medicaid Services not to cover anti-obesity medications, impacting many beneficiaries. The potential benefits of these medications—which are also being studied for Alzheimer's—relate to the broader health impacts and policy gaps in U.S. healthcare reform. The key concept of Alzheimer's is linked through ongoing research about the drugs' broader health benefits.
Article found on: time.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here